Medigen Vaccine Biologics Income Statement

Financials in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2015 - 2019
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	2015 - 2019
Revenue	594.96	605.64	389.62	365.04	3,281	11.51	Upgrade
Revenue Growth (YoY)	-8.21%	55.44%	6.73%	-88.87%	28413.03%	927.41%	Upgrade
Cost of Revenue	264.82	209.22	159.4	577.64	975.96	3.87	Upgrade
Gross Profit	330.14	396.42	230.22	-212.6	2,305	7.64	Upgrade
Selling, General & Admin	294.83	320.58	243.44	183.67	148.21	91.96	Upgrade
Research & Development	202.94	221.51	1,201	1,140	1,193	679.56	Upgrade
Operating Expenses	497.78	542.09	1,444	1,324	1,341	771.52	Upgrade
Operating Income	-167.64	-145.67	-1,214	-1,536	963.73	-763.88	Upgrade
Interest Expense	-8.79	-18.89	-37.57	-26.89	-6.02	-16.42	Upgrade
Interest & Investment Income	32.1	46.25	83.28	7.61	2.74	1.48	Upgrade
Currency Exchange Gain (Loss)	-14.42	38.35	-0.33	28.86	7.52	4.15	Upgrade
Other Non Operating Income (Expenses)	1.51	-1.62	8.61	32.25	-0.07	0.19	Upgrade
EBT Excluding Unusual Items	-157.23	-81.57	-1,160	-1,494	967.9	-774.49	Upgrade
Gain (Loss) on Sale of Investments	-	-	-	-	-	-0.06	Upgrade
Gain (Loss) on Sale of Assets	-8.43	0.41	-	-	-	19.73	Upgrade
Other Unusual Items	0.01	0.7	-	19.86	442.36	80.54	Upgrade
Pretax Income	-165.64	-80.47	-1,160	-1,475	1,410	-674.28	Upgrade
Net Income	-165.64	-80.47	-1,160	-1,475	1,410	-674.28	Upgrade
Net Income to Common	-165.64	-80.47	-1,160	-1,475	1,410	-674.28	Upgrade
Shares Outstanding (Basic)	329	329	328	323	319	277	Upgrade
Shares Outstanding (Diluted)	329	329	328	323	321	277	Upgrade
Shares Change (YoY)	0.01%	0.10%	1.50%	0.73%	15.82%	20.08%	Upgrade
EPS (Basic)	-0.50	-0.24	-3.53	-4.56	4.42	-2.43	Upgrade
EPS (Diluted)	-0.50	-0.24	-3.53	-4.56	4.39	-2.43	Upgrade
Free Cash Flow	-28.29	6.46	-521.25	-1,353	446.26	-689.22	Upgrade
Free Cash Flow Per Share	-0.09	0.02	-1.59	-4.18	1.39	-2.49	Upgrade
Gross Margin	55.49%	65.45%	59.09%	-58.24%	70.25%	66.36%	Upgrade
Operating Margin	-28.18%	-24.05%	-311.54%	-420.85%	29.37%	-6638.40%	Upgrade
Profit Margin	-27.84%	-13.29%	-297.68%	-403.95%	42.98%	-5859.74%	Upgrade
Free Cash Flow Margin	-4.75%	1.07%	-133.78%	-370.64%	13.60%	-5989.55%	Upgrade
EBITDA	-47.12	-26.16	-1,098	-1,423	1,072	-653.8	Upgrade
EBITDA Margin	-7.92%	-4.32%	-281.86%	-	32.67%	-	Upgrade
D&A For EBITDA	120.51	119.5	115.64	112.91	108.34	110.08	Upgrade
EBIT	-167.64	-145.67	-1,214	-1,536	963.73	-763.88	Upgrade
EBIT Margin	-28.18%	-24.05%	-	-	29.37%	-	Upgrade

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.